Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is biomarkers in multiple sclerosis!
Quiz|Articles|October 25, 2026 (Updated: October 23, 2026)
NeurologyLive® Brain Games: October 25, 2026
Author(s)Louie Pasculli, Marco Meglio
Listen
0:00 / 0:00
Key Takeaways
- Weekly publication cadence is Sunday morning, with content written by physicians, clinicians, and neurological care and advocacy experts.
- Questions span major neurology domains, including dementia/Alzheimer disease, epilepsy, headache, movement disorders, multiple sclerosis, neuromuscular and sleep disorders, and stroke.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is recent advances in gene therapies.
Advertisement
Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions on a variety of clinical and historical neurology topics, written by physicians, clinicians, and experts in the fields of neurological care and advocacy.
Test your mettle each week with 3 questions that cover a variety of aspects in the field of neurology, with a focus on dementia and Alzheimer disease, epilepsy and seizure disorders, headache and migraine, movement disorders, multiple sclerosis, neuromuscular disorders, sleep disorders, and stroke and cerebrovascular disease.
This week's questions includes the theme of recent advances in gene therapies!
Interested in submitting quiz questions? Contact our editor, Marco Meglio, via email:
In November 2025, the FDA approved Itvisma, an AAV-based gene therapy for SMA. Which feature most clearly distinguishes Itvisma from the earlier Zolgensma product?
A 7-year-old ambulatory boy with genetically confirmed Duchenne muscular dystrophy (DMD) is being evaluated for delandistrogene moxeparvovec (Elevidys). Which consideration is particularly important following the FDA's November 2025 label revision?
A phase 1 clinical trial published in 2026 evaluated BBM-P002, an investigational gene therapy for Parkinson disease. Which approach distinguishes this therapy from earlier gene therapies targeting aromatic L-amino acid decarboxylase (AADC) alone?
How did you do on this week's quiz? Let us know with a response to the poll below. Don't forget to share and compare your results with your friends!
How many questions did you get correct?
Advertisement
Related to this article
A secondary analysis of the BRIDGE-TNK trial found tenecteplase before thrombectomy improved functional outcomes in cardioembolic but not atherosclerotic stroke.
At a NeurologyLive and Targeted Oncology Clinical Forum in Houston, Kevin J. Bielamowicz, MD, of Arkansas Children’s Hospital, discussed how incidental diagnosis and limited awareness of systemic therapy continue to delay care for patients with NF1-associated plexiform neurofibromas.
Phase 3 data show the oral BTK inhibitor reduced annualized relapse rate by 35.2% and 31.2% vs teriflunomide, with no liver safety signal or Hy's Law cases.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 23, 2026.
A secondary analysis of the DISTAL trial found endovascular therapy's benefit depended more on stroke severity than on prior thrombolysis treatment.
The FDA set a first quarter 2027 goal date for troriluzole in spinocerebellar ataxia and plans an advisory committee after a 2025 complete response letter.
A pooled analysis of 4 randomized trials found that more time with blood pressure below 130 mmHg after intracerebral hemorrhage reduced recurrent stroke risk.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Remibrutinib Lowers Relapse Rate vs Teriflunomide in Relapsing MS
2
FDA Accepts Troriluzole NDA Resubmission for Spinocerebellar Ataxia
3
Tenecteplase Benefit Before Thrombectomy Varies by Stroke Cause, Study Shows
4
Real-World Data Show Switch to Subcutaneous Ocrelizumab Well Tolerated
5